Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Hemolytic-uremic syndrome Stories

2014-03-31 16:27:38

OAKLAND, Calif., March 31, 2014 /PRNewswire/ -- Machaon Diagnostics today announced the availability of its "aHUS Genetic Panel(TM)" (patent pending) to genetically confirm atypical Hemolytic Uremic Syndrome (aHUS) with a turnaround time of 48 hours. The 48 hour timeframe is a dramatic advancement over other approaches which offer results in 4-13 weeks. The speed of the aHUS Genetic Panel(TM) allows the test to impact patient care in acute settings, enabling doctors to better serve...

2014-03-10 08:29:22

- Phase 2 Clinical Trial in aHUS and Other TMAs Expected to Begin Next Quarter - SEATTLE, March 10, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in ex vivo studies of endothelial activation relevant to the pathophysiology of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA)....

2014-01-16 08:27:51

New testing approach uses Next Gen Sequencing platform MILWAUKEE, Jan. 16, 2014 /PRNewswire/ -- BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of a comprehensive genetic evaluation using next generation sequencing (NGS) technology for patients with Atypical Hemolytic Uremic Syndrome (aHUS). BloodCenter is among the first to offer clinical diagnostics using NGS, providing a dramatically shortened timeline for obtaining test results for this...

2013-11-10 00:21:29

- New Data from the Largest Prospective Trial of Adult Patients with aHUS and First Prospective Trial in Pediatric Patients with aHUS Confirm the Safety and Efficacy Profile of Soliris -- - ASN Meeting Also Features Three-year Update Data Highlighting Long-term Benefits of Chronic Soliris Therapy in Patients with aHUS - CHESHIRE, CT, Nov. 9, 2013 /CNW/ - Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that researchers presented data from four clinical trials, all...

2013-09-10 23:01:16

Attorney Bill Marler's reaction to a press conference held by Federico's Mexican Restaurant, whose Litchfield Park, AZ, restaurant was the alleged source of an E. coli outbreak. LITCHFIELD PARK, AZ (PRWEB) September 10, 2013 William Marler, the Seattle-based attorney who represents over a dozen victims of the E. coli O157:H7 outbreak among customers of the Litchfield Park, Arizona Federico’s restaurant[1], responded to the restaurant chain’s announcement today that it had...

2013-09-09 12:27:47

Novel Humanized Antibody Approach May Lead to Safer, More Cost Effective Treatment CLEVELAND, Sept. 9, 2013 /PRNewswire-USNewswire/ -- NovelMed Therapeutics (www.novelmed.com) announced the receipt of a combined $1.43 million SBIR Grant from the NIH. The first installment of the award (for $542,572) will be used to evaluate NovelMed's lead candidate's therapeutic superiority for treating Paroxysmal Nocturnal Hemoglobinuria (PNH). Subsequent funding, to be released on demonstration...

2013-04-18 16:27:57

-vaccine to be used under import permit on cattle farms to control serious human illness- BELLEVILLE, ON, April 18, 2013 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that its E. coli O157 cattle vaccine (Econiche®) is being shipped to Sweden for on-farm studies in some Swedish cattle herds. The Swedish National Veterinary Institute, Swedish Animal Health Service AB and the...

2013-01-09 20:20:53

OTTAWA, Jan. 9, 2013 /CNW/ - Why you should take note Today, an additional case of E.coli O157:H7 was confirmed in Ontario as part of this outbreak. This brings Ontario's number of cases to 5 and the total to 16. Products contaminated with E. coli O157 can pose a serious public health risk. The Public Health Agency of Canada has been working with its health and food safety partners on an investigation into 16 cases of E. coli O157:H7 illness. There are six cases in New...

2013-01-09 00:20:45

OTTAWA, Jan. 8, 2013 /CNW/ -Why you should take note Products contaminated with E. coli O157 can pose a serious public health risk. The Public Health Agency of Canada has been working with its health and food safety partners on an investigation into 15 cases of E. coli O157:H7 illness. There are six cases in New Brunswick, five in Nova Scotia and four in Ontario. The majority of cases are recovered or are recovering. Status Investigations into outbreaks of food-borne illness...

2012-08-07 10:25:49

BELLEVILLE, ON, Aug. 7, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that the Veterinary Medicines Directorate (VMD) of the Department for the Environment, Food and Rural Affairs in United Kingdom has approved the importation of the Company's cattle vaccine against E. coli O157 for use under the conditions of a Special Treatment Certificate (STC). Dr. Chris Low, Director...